Abstract
Giant cell arteritis (GCA) is a medical emergency characterized by systemic inflammation and critical ischemia. Neuro-ophthalmic complications occur early, with permanent vision loss in up to one fifth of patients. This mainly results from failure of prompt recognition and treatment. Diagnosis of GCA is often preceded by unrecognized symptoms, including constitutional upset and jaw claudication. Features predictive of permanent visual loss include jaw claudication and temporal artery abnormalities on physical examination. These patients often do not mount high inflammatory responses. Modern imaging techniques show diagnostic promise, and have led to an increased recognition of major artery involvement in GCA. However, temporal artery biopsy remains the gold standard for investigation. Intimal hyperplasia on histologic examination is associated with neuro-ophthalmic complications. The mainstay of therapy remains corticosteroids. Experience using conventional disease-modifying drugs has been mixed, and biologic therapies require further evaluation for their steroid-sparing potential.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Liu NH, LaBree LD, Feldon SE, et al.: The epidemiology of giant cell arteritis. Ophthalmology 2001, 108:1145–1149.
Smeeth L, Cook C, Hall AJ: Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis 2006, 65:1093–1098.
Rauzy O, Fort M, Nourhashemi F, et al.: Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis. Ann Rheum Dis 1998, 57:380–382.
Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al.: Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine 2000, 79:283–292.
Salvarani C, Cimino L, Macchioni P, et al.: Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005, 53:293–297.
Loddenkemper T, Pankaj P, Katzan I, Plant GT: Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry 2007, 78:1255–1259.
Nesher G, Berkun Y, Mates M, et al.: Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004, 83:114–122.
Galor A, Lee MS: Slowly progressive vision loss in giant cell arteritis. Arch Ophthalmol 2006, 124:416–418.
Cohen S, Gardner F: Bilateral choroidal ischemia in giant cell arteritis. Arch Ophthalmol 2006, 124:922.
Lee AG, Tang RA, Feldon SE, et al.: Orbital presentations of giant cell arteritis. Graefe’s Arch Clin Exp Ophthalmol 2001, 239:509–513.
Danesh-Meyer H, Savino PJ, Gamble GG: Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005, 112:1098–1103.
Hayreh SS, Zimmerman B: Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003, 110:1204–1215.
Makkuni D, Bharadwaj A, Wolfe K, et al.: Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford) 2008, 47:488–490.
Smetana GW, Shmerling RH: Does this patient have temporal arteritis? JAMA 2002, 287:92–101.
Nuenninghoff DM, Hunder GG, Christianson TJH, et al.: Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis. Arthritis Rheum 2003, 48:3522–3531.
Weyand CM, Goronzy JJ: Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999, 42:844–853.
Weyand CM, Tetzlaff N, Bjornsson J, et al.: Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997, 40:19–26.
Hernandez-Rodriguez J, Segarra M, Vilardell C, et al.: Tissue production of pro-inflammatory cytokines (IL-1βα, TNF-α and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004, 43:294–301.
Hernandez-Rodriguez J, Segarra M, Vilardell C, et al.: Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis. Circulation 2003, 107:2428–2434.
Mahr A, Saba M, Kambouchner M, et al.: Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis 2006, 65:826–828.
Boyev LR, Miller NR, Green WR: Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol 1999, 128:211–215.
Danesh-Meyer HV, Savino PJ, Eagle RC, et al.: Low diagnostic yield with second biopsies in suspected giant cell arteritis. J neuro-ophthalmol 2000, 20:213–215.
Chakrabarty A, Franks AJ: Temporal artery biopsy: is there any value in examining biopsies at multiple levels? J Clin Pathol 2000, 53:131–136.
Achkar AA, Lie JT, Hunder GG, et al.: How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994, 120:987–992.
Ray-Chaudhuri N, Ah Kine D, Tijani SO, et al.: Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 2002, 86:530–532.
Schmidt WA, Kraft HE, Vorpahl K, et al.: Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997, 337:1336–1342.
Murgatroyd H, Nimmo M, Evans A, MacEwen C: The use of ultrasound as an aid in the diagnosis of giant cell arteritis: a pilot study comparing histological features with ultrasound findings. Eye 2003, 17:415–419.
Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JPA: Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005, 142:359–369.
Turlakow A, Yeung HWD, Pui J, et al.: Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 2001, 161:1003–1007.
Blockmans D, de Ceuninck L, Vanderschueren S, et al.: Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006, 55:131–137.
Narvaez J, Narvaez JJ, Nolla JM, et al.: Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology 2005, 44:479–483.
Bley TA, Uhl M, Carew J, et al.: Diagnostic value of high-resolution MR imaging in giant cell arteritis. Am J Neuroradiol 2007, 28:1722–1727.
Bley TA, Markl M, Schlep M, et al.: Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology 2008, 47:65–67.
Heyreh SS, Zimmerman B, Kardon RH: Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002, 80:353–367.
Proven A, Gabriel SK, Orces C, et al.: Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703–708.
Chan CCK, Paine M, O’Day J: Steroid management in giant cell arteritis. Br J Ophthalmol 2001, 85:1061–1064.
Faroozan R, Deramo VA, Buono LM, et al.: Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003, 110:539–542.
Chevalet P, Barrier J-H, Pottier P, et al.: A randomized, multicenter, controlled trial using intravenous pulses of Methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000, 27:1484–1491.
Mazlumzadeh M, Hunder GG, Easley KA, et al.: Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids. Arthritis Rheum 2006, 54:3310–3318.
Nesher G, Berkun Y, Mates M, et al.: Low-dose aspirin and prevention of cranial ischaemic complications in giant cell arteritis. Arthritis Rheum 2004, 50:1332–1337.
Weyand CM, Kaiser M, Yang H, et al.: Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002, 46:457–466.
Jover JA, Hernandez-Garcia C, Morado IC, et al.: Combined treatment of giant cell arteritis with methotrexate and prednisone. Ann Intern Med 2001, 134:106–114.
Spiera RF, Mitnick HJ, Kupersmith M, et al.: A prospective double-blind randomized placebo controlled trial of methotrexate in the treatment of giant cella arteritis. Clin Exp Rheumatol 2001, 19:495–501.
Hoffman GS, Cid MC, Helklmann DB, et al.: A multicentre randomized double blind placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002, 46:1309–1318.
Mahr AD, Jover JA, Spiera RF, et al.: Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007, 56:2789–2797.
De Silva M, Hazleman BL: Azathioprine in giant cell arteritis/ polymyalgia rheumatica: a double blind study. Ann Rheum Dis 1986, 45:136–138.
Cantini F, Niccoli L, Salvarani C, et al.: Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001, 44:2933–2935.
Tan AL, Holdsworth J, Pease C, et al.: Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003, 62:373–374.
Andonopoulos AP, Meimaris N, Daoussis D, et al.: Experience with infliximab (anti-TNF-α monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003, 62:1116.
Salvarani C, Macchioni P, Manzini C, et al.: Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med 2007, 146:631–639.
Hoffman GS, Cid MC, Rendt-Zagar KE, et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 2007, 146:621–630.
Martinez-Taboada VM, Rodriguez-Valverde V, Carreño L, et al.: A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2007 (Epub ahead of print).
Bhatia A, Ell PJ, Edwards JCW: Anti-CD20 monoclonal antibody (Rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005, 64:1099–1100.
Brown MM, Brown GC, Sharma S, et al.: Utility values associated with blindness in an adult population. Br J Ophthalmol 2001, 85:327–331.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Borg, F.A., Salter, V.L.J. & Dasgupta, B. Neuro-ophthalmic complications in giant cell arteritis. Curr Allergy Asthma Rep 8, 323–330 (2008). https://doi.org/10.1007/s11882-008-0052-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11882-008-0052-4